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In a global effort for scientific transparency, it has become feasible and good practice to
share experimental data supporting novel findings. Consequently, the amount of publicly
available MS-based proteomics data has grown substantially in recent years. With some notable
exceptions, this extensive material has however largely been left untouched. The time has now
come for the proteomics community to utilize this potential gold mine for new discoveries,
and uncover its untapped potential. In this review, we provide a brief history of the sharing of
proteomics data, showing ways in which publicly available proteomics data are already being
(re-)used, and outline potential future opportunities based on four different usage types: use,
reuse, reprocess, and repurpose. We thus aim to assist the proteomics community in stepping
up to the challenge, and tomake themost of the rapidly increasing amount of public proteomics
data.
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1 Introduction
1.1 Background
Historically, a large proportion of the proteomics community
was reticent to openly share the data they produced. How-
ever, the sharing of not only the knowledge obtained through
proteomics experiments (through scientific publications), but
also of the underlying data, has increasingly become standard
practice, and is now even mandatory or strongly advised in
many of the relevant scientific journals [1–3]. In addition, a
number of funders (e.g. the Wellcome Trust and the NIH)
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are enforcing the public deposition of data from projects they
fund as a way tomaximize the value of the funds provided. As
a result, the amount of publicly shared MS-based proteomics
data has grown substantially, both in terms of number of
submission and total data amount, as illustrated in Fig. 1.
Two key factors strongly contributed to this success: first,
the sharing of the data has becomemucheasierwith the devel-
opment of user-friendly tools and infrastructure; and second,
the proteomics community, triggered by scientific journals
and funders, has now agreed that it is good scientific practice
to make the underlying data available when publishing novel
findings.
There were several challenges to overcome in order to get
to this point, see Fig. 2. The first of these challenges was the
need for central and long-term public repositories to store
the generated data. Several such generic repositories are now
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Figure 1. The amount of publicly available proteomics data is
increasing, here indicated by the monthly submission statistics
for PRIDE from June 2012 to May 2015. The x-axis represents
the months and the y-axis the monthly number of submissions.
The size of the bubbles indicate the data amount submitted each
month. Note that the cumulative size of PRIDE data reached the
100 TB milestone in April 2015.
available, for example PRIDE [4], GPMDB [5], PeptideAtlas
[6], and MassIVE (http://massive.ucsd.edu/ProteoSAFe)
for shotgun results; and PASSEL [7], SRMAtlas
(http://www.srmatlas.org), and Panorama [8] for targeted
proteomics quantification data. More specific databases have
also been established, related to: diseases, for example TBDB
for tuberculosis [9]; organisms, for example ProteomicsDB
[10] and the Human Proteome Map [11] for the human
proteome, and pep2pro forArabidopsis [12]; or subproteomes,
for example CSF-PR [13] for cerebrospinal fluid or TOPPR
[14] and TopFIND [15] for in vivo cleaved proteins. For a
comprehensive overview of the current proteomics databases
and repositories, please see Perez-Riverol et al. [16].
The next milestone was the development of data-
sharing standards and associated software libraries,
allowing ready access to otherwise proprietary data for-
mats [17]. This ongoing endeavor, led by the HUPO-
PSI (Human ProteomeOrganization−Proteomics Standards
Initiative−http://www.psidev.info), has resulted in key data
standards for the field, including mzML (for MS data),
mzIdentML (for peptide/protein identification data), mzTab
(for peptide/protein identification and quantification data),
mzQuantML (for peptide/protein quantification data), and
TraML (for transition lists in targeted proteomics approaches)
[18–22]. Importantly, support for these standards is provided
through software libraries or tools such as ProteoWizard [23],
PRIDE Converter [24, 25], mzidLibrary [26], and PRIDE In-
spector [27]. Successful adoption of these standards is more-
over demonstrated by the existence of import and/or export
capabilities in many of the most popular software in the field.
The final piece of the puzzle was the creation of an over-
arching system to share submitted data between reposito-
ries, and to develop a single, user-friendly submission work-
flow. This goal was obtained with the establishment of the
ProteomeXchange consortium [28], which connects some
of the most used proteomics databases (at present PRIDE,
MassIVE, PASSEL, and PeptideAtlas) with a single submis-
sion system and the use of unique identifiers that can be
tracked across these databases and over time.
However, while publicly available proteomics data repre-
sent an invaluable resource for extracting new knowledge
[29], they have so far, with a few notable exceptions, remained
largely unused. At the same time, data reprocessing has be-
come the standard in related fields, such as genomics, see
Rung et al. [30]. The time has now come for the field of pro-
teomics to also start utilizing its public data as a test bed for
novel ways of interpreting proteomics data, and as a potential
goldmine for new discoveries. The heterogeneous nature of
the accumulated data also provides a global view on the state
Figure 2. The major mile-
stones that enabled efficient
proteomics data sharing: (A)
standard data formats for shar-
ing proteomics data, (B) data
format converters and software
exporters able to generate
output in the standard formats,
(C) tools for simplifying the
submission of proteomics
data to central proteomics
repositories, and (D) central
proteomics repositories that
store and disseminate public
proteomics data, here indicated
by the main ProteomeXchange
member repositories.
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Figure 3. The four ways in
which public proteomics data
can be utilized: (i) use, (ii) reuse,
(iii) reprocess, and (iv) repur-
pose. See main text for details.
of the art and the evolution of the field as a whole, and reduces
bias toward specific protocols or instruments.
There are four ways in which these shared proteomics
data can be utilized: (i) use, (ii) reuse, (iii) reprocess, and (iv)
repurpose (Fig. 3), each of which will be described in detail in
the following sections.
1.2 Data use through protein knowledge-bases
An example of the direct use of proteomics data is by looking
up information about a given protein as indexed in an online
protein knowledge-base, such as UniProt [31] or neXtProt
[32]. This does not result in knowledge beyond what has al-
ready been published, but does provide the means to un-
derstand the current context of the protein(s) in question.
For example, MS proteomics data deposited in public repos-
itories is used by UniProt and neXtProt to enrich sequence
annotations at the level of the evidence that supports protein
existence (isoforms and variant sequences included). This in-
formation is provided to users in two ways: (i) via the protein
evidence values, or (ii) through cross-references to proteomics
resources (e.g. PRIDE and PeptideAtlas, among others). The
next step will be the incorporation of PTMs based on the in-
formation available in proteomics repositories, as is already
done in databases such as PhosphoSitePlus [33]. Currently,
the main integration of this information occurs via manual
curation of relevant publications.
1.3 Reusing data to improve proteomics approaches
In the case of reuse, information is not only extracted, but
also reused in new experiments with the potential of gen-
erating new knowledge. One of the best examples is the
reuse of SRM transitions generated by others, via SRMAt-
las (http://www.srmatlas.org) or Panorama [8], where exist-
ing transitions for specific proteins in a given instrumental
setup can be found. Note that it is also possible to develop
tools to look for novel transitions in publicly available shotgun
datasets. For example, MRMaid [34], PeptidePicker [35, 36],
and ProteomicsDB [10] do this by reusing identification data
coming from PRIDE and other sources.
One particular type of data reuse, already popular in
other disciplines, is to analyze data from a large number
of publications/datasets in a combined way, so-called meta-
analysis studies. Indeed, the availability of large amounts of
proteomics data has the advantage that it can be used for
data mining purposes, that is extracting aggregated knowl-
edge from the data provided by the community world-
wide. The principle being: the more data, the better the
understanding.
In fact, meta-analysis studies can indeed provide new in-
formation that can be directly applied in proteomic analytic
workflows.One example is a study aimed at improving theun-
derstanding of the cleavage mechanism and performance of
trypsin [37, 38], a crucial parameter in proteomic workflows.
By inspecting the cleavage profile of all peptide identifications
deposited in PRIDE, it was possible to train an algorithm that
predicts trypsin cleavage sites, a functionality that is available
through a web interface [39]. Similarly, the study of deposited
data was used to monitor peptide elution during LC, and en-
abled the optimization of gradients in silico [40]. Public MS
data have also been mined to study the fragmentation pat-
tern of different fragmentation methods [41], and to predict
peptide fragmentation patterns [42].
PRIDE data have also been reused through the combina-
tion of data from significantly different experimental setups.
For example, Klie et al. [43] used a noise-tolerant algorithm
to extract new knowledge from the datasets that comprise the
C© 2015 The Authors. Proteomics published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.proteomics-journal.com
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HUPO Plasma Proteome Project [44]. Another example can
be found in Mu¨ller et al. [45], where two proteomics datasets
related to the CNS were remapped against a more recent ver-
sion of the protein sequence database used in the original
studies. This enabled the authors to look for the expression
of specific splice isoforms from CNS-related genes. Finally,
in another example of PRIDE data reuse, UniProtKB was
determined to be the most suitable reference database for
long-term proteomics data storage [46].
Large-scale biological results can also be reused because
of their indexing in databases, notably via so-called BioMarts
[47] or more recently, web services [48,49]. Mining such data
in their biological context may allow the extraction of novel
biomarkers, as discussed in Griss et al. [50].
1.4 Reusing data via spectral libraries and spectral
archives
Additional spectrum interpretation strategies such as
de novo sequencing or spectral databases are also promis-
ing approaches to increase the identification rate of spectra
in MS-based proteomics. The creation of spectral libraries
most strongly benefits from the growing amount of shared
data [51, 52]. Several repositories, including PeptideAtlas,
GPMDB, and PRIDE, and research groups such as the one
at NIST (National Institute of Standards and Technology),
provide spectral libraries for different species, which can in
turn be used to perform spectral searches.
When assessing the similarity of spectra, spectral cluster-
ing can be performed [53–56]. While transitive identifications
and consensus or representative spectra have been reported
in all of these studies, the conceptwas further developed in the
creation of spectral archives [57]. Spectral clustering has since
been adopted by PRIDE to make quality assessments on the
submitted data at the peptide to spectrum match (PSM) level
[58]. After clustering, a representative spectrum is built for
all peptides consistently identified across different datasets.
The accuracy of this representative spectrum thus improves
with every new dataset submitted to PRIDE, allowing an au-
tomated quality assessment of the PSM data. The key role of
proteomics repositories in the further development of spec-
tral archives was highlighted by H. Lam, who envisioned a
future where it would be possible to perform a centralized
data analysis by performing spectral searches [59].
1.5 Data reprocessing through improved
bioinformatic approaches
In the case of reprocess, the data are reprocessed with the in-
tention of obtaining new knowledge or to provide an updated
view on the results. This can result in novel findings, but
mainly serves the same purpose as the original experiment.
For example, a shotgun dataset can be reprocessed with a
different algorithm or an updated sequence database.
Perhaps, the simplest step one can take when reprocess-
ing a dataset is to analyze the potential effect of adding com-
mon contaminants if these were not included in the orig-
inal search, as this makes it possible to rule out common
false positive findings. For example, it could potentially turn
out that an important finding could be better explained by a
match with a common contaminant such as human keratin
or trypsin [60]. For instance, a standard list of contaminants
can be found in the common Repository of Adventitious Pro-
teins (cRAP—http://www.thegpm.org/crap), provided by the
GPM team.
The gene and protein sequence databases that identifica-
tion depends on are constantly evolving and improving [46].
This means that reprocessing a proteomics dataset with an
updated version of the gene or protein database can result
in improved findings. This is particularly true for poorly an-
notated species. In addition, updating a database to include
known isoforms and/or mutations will provide a different
view of the dataset.
Analogously, the software used to process proteomics data
is also constantly improving, either by the further develop-
ment of existing algorithms or by the establishment of new
analysis approaches. The use of up-to-date techniques for the
reprocessing of older datasets allows valuable information to
be extracted from the acquired data without the need to re-
peat the experiment. This is particularly important for data
from valuable or unique samples, where it ensures that as
much information as possible can be obtained from these
samples.
It should be noted that some of the existing proteomics
databases, most notably GPMDB [5] and PeptideAtlas [6],
routinely reprocess their data using dedicated bioinformatics
tools and pipelines. GPMDB makes use of the X!Tandem
search engine [61], whereas PeptideAtlas employs the Trans
Proteomic Pipeline [62]. The data reprocessed by Peptide-
Atlas is organized into different builds, each including data
from a single proteome (e.g. human) or subproteome (e.g.
human plasma). Each build is generated based on the raw
MS/MS spectra submitted to PeptideAtlas over the years, or
from data deposited in other public repositories, for example
PRIDE. In addition tohuman,many species nowhave specific
PeptideAtlas builds, including, for example Candida albicans
[63] and horse [64], among many others.
The GPMDB pipeline reprocesses the MS/MS data pro-
vided by users or raw data stored in other repositories, such
as those from ProteomeXchange. Till the end of 2014, some
of the reprocessed datasets were highlighted on aweekly basis
on the GPM website (http://www.thegpm.org/news.html).
Both resources, PeptideAtlas and GPMDB, are also join-
ing efforts in the context of the Chromosome-based (C-) and
Biology/Disease (B/D) Human Proteome Projects (HPP) [65,
66], together with neXtProt and the antibody-based resource
Human Proteome Atlas [67]. This is a clear example of the
utility of large-scale and centralized (re-)processing, as it can
ensure consistent processing and thus comparable results.
The C-HPP team provides regular updates on the status of
C© 2015 The Authors. Proteomics published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.proteomics-journal.com
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completion of the human proteome and on the enumeration
of the so-called “missing” proteins, that is proteins that have
never been reliably detected experimentally [68].
1.6 Reusing and reprocessing enables scientific
discussion
Perhaps, the most common current use case for shared pro-
teomics data is the evaluation of existing results, often as part
of the manuscript review process. This can be achieved by
inspecting the data as provided by the authors, or by repro-
cessing the raw data by mimicking the original processing
and then assessing the reproducibility of the results. The
evaluation can be carried out at two levels: at the level of
the individual PSMs, or at the level of the entire dataset. An
example of the former is the checking of spectrum anno-
tation quality, for example for post-translationally modified
peptides. This can, for example, be achieved via the use of
visualization tools such as MS-viewer [69], Scaffold Viewer,
Thermo MSF Viewer, Peptizer [70], ProteoIDViewer [26], or
TOPPView [71], among others.
For validation at the dataset level, tools such as PRIDE In-
spector [27] and PeptideShaker [72], can be used to inspect
and reprocess the data, respectively. Note that PeptideShaker
provides a direct connection to PRIDE datasets to enable their
streamlined reprocessing. The need for visual and interactive
solutions should be noted here, as this can dramatically im-
prove the validation procedure compared to looking at static
images or tables [73].
One of the most famous examples of data discussion,
involving both visual inspection and reprocessing, is related
to the proteomics investigations of Tyrannosaurus rex fossil
bone samples. The initial publications by Asara et al. [74, 75]
proved controversial in the proteomics community (see, e.g.
[76,77]). As a consequence, the authors decided to make their
data publicly available (PRD000074 in PRIDE), such that
other researchers could inspect and reprocess the data them-
selves. Among others, this resulted in Bern et al. concluding
that the original data did not contain any T. rex proteins [78].
The debate remains to be definitively settled, but the spirited
scientific discussion highlights the importance of making
the underlying data for published work available so that all
sides can scientifically and reasonably discuss the findings
based on the same evidence.
Another example is a study by Bromenshenk et al., which
claimed to have found a link between viral and fungal con-
tamination and the ongoing honey bee colony collapse dis-
order [79], a study that sparked global public interest. How-
ever, after the authors shared the data with others (available
on request only), it became clear that this too could be a
false positive outcome due to the systematic misidentifica-
tion of bee-derived spectra as viral or fungal sequences, due
to searching against a protein sequence database that lacked
all honey bee sequences [80–82]. This discussion too still
continues; however, as the same dataset was recently used
to illustrate the opinion that, in order to improve statistical
power, researchers should remove irrelevant peptides from
the database before searching [83]. Here again, the inspection
and reprocessing of the original experimental data enabled
a scientific discussion and made it possible to collectively
improve the scientific output, and paved the way for new
discoveries [84].
More recently, there is an ongoing debate about the two
drafts of the human proteome published in Nature in 2014
[10, 11]. Both studies provided an exemplary precedent by
sharing all generated data (available as datasets PXD000561
and PXD000865 in PRIDE). This has enabled the community
to start a discussion about the reliability of the results, see for
instance Ezkurdia et al. [85].
1.7 Data repurposing in proteogenomics studies
Finally, when repurposing public data, these data are consid-
ered in light of a question or a context that is entirely different
from the original study. It should be noted that repurposing
thus often involves reprocessing as well. One example is the
reprocessing of proteomics datasets to improve genome an-
notation in so-called proteogenomics approaches. For exam-
ple, Brosch et al. reprocessed shotgun proteomics data from
PeptideAtlas to discover novel protein-coding genes and to
improve gene annotation in the mouse genome [86]. At the
time, they found alternatively spliced translations from 53
genes along with ten entirely novel protein-coding genes.
Another example is provided by LNCipedia [87], a resource
for human long noncoding RNAs. PRIDE-based reanalysis
of human proteomics data has provided evidence that some
long-noncodingRNAs in LNCipedia are potentially translated
to proteins [87].
In another proteogenomics study, Ezkurdia et al. repro-
cessed public proteomics data available in GPMDB and Pep-
tideAtlas to identify peptides covering 35% of the genes anno-
tated by the GENCODE consortium for the human genome
[88]. Among other findings, they found that 150 genes ex-
pressedmultiple alternative protein isoforms.Additionally, in
a second analogous study, they concluded that thehumanpro-
teome was composed of around 19 000 protein-coding genes
[89], a lower number by around 1000 genes than the canonical
assumption. In a related recent third study, they also reused
public proteomics data from the same resources to suggest
that most genes had a single dominant isoform at the protein
level [90].
Existing proteomics data can also be reused in proteoge-
nomics approaches. In a recent study devoted to psoriasis [91],
the generated data were integrated with public data available
in PRIDE (dataset PRD000053), proteomics data from other
studies, and gene expression data available in the GEO (Gene
Expression Omnibus) database [92]. As a final example in
this section, Zhu et al. employed public proteomics data to
develop a tool that can identify differentially regulated splice
variants [93].
C© 2015 The Authors. Proteomics published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.proteomics-journal.com
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Because of the massive amounts of publicly available data
and their inherent heterogeneity, the chances of reliably de-
tecting protein expression evidence is higher in such repro-
cessing and repurposing approaches. However, due to the
unconventional sequence population of the databases in pro-
teogenomics, and their often extensive size, the estimation of
false positive rates by traditional approaches can be impaired
[83,94]. In the near future, it is therefore expected that the cre-
ation of such sequence databases will be coupled to ribosome
profiling data, to discern the exact start of translation of pu-
tative proteins [95]. Indeed, tools such as ProteoFormer can
already be used to generate proteomics-compatible protein
sequence databases from such ribosome profiling data [96].
1.8 Reprocessing for better PTM localization and
repurposing to find new PTMs
Finding and localizingPTMsare essential tasks in proteomics
data analysis [97], and for this purpose multiple PTM local-
ization scores have been developed [98], for example A-score
[99], PTM score [100], MD-score [101], phosphoRS [102], and
D-score [103]. Setting a threshold for these scores is, how-
ever, challenging, and solutions have only recently been es-
tablished [104,105]. If such approacheswerenot applied in the
original analysis, it is worth reprocessing the data, as this can
dramatically improve the quality of the PTM annotation on
the protein sequences. The reported location of specific PTMs
can furthermore be refined using additional techniques, for
example by considering the three-dimensional structure of
the protein as indicated by Vandermarliere et al. [106].
It is also possible to repurpose existing datasets to look for
PTMs that were not considered in the original analysis, for
example via mass-tolerant database searches [107]. This task
is made difficult by the substoichiometric nature of mod-
ified proteins, thus usually requiring experimental enrich-
ment techniques to enable detection [108–110]. It is therefore
often not straightforward to simply reprocess a dataset to find
suchmodifications, but here again, the large amount of public
data increases the probability to uncover modified peptides.
Successful studies have therefore used enriched phospho-
proteomics datasets to find peptides with unusual modifica-
tions that had a high probability of being co-enriched. Matic
et al. [111] reanalyzed a mouse dataset to identify a total of 88
mono–ADP-ribosylation sites in 79 different proteins, with
eight sites found modified also by ribose phosphate, a mod-
ification derived from ADP-ribose. In the reanalysis of an-
other mouse dataset, Hahne and Ku¨ster [112] discovered an
O-GlcNAc-6-phosphate modification on 23 peptides corre-
sponding to 11 proteins.
1.9 Toward quantitative, across-source reprocessing
At the moment few repositories contain quantitative pro-
teomics data, though it is possible to include quantitative in-
formation in data submissions to proteomics resources such
as PRIDE. However, it is not yet possible to visualize and
inspect this information properly due to a lack of suitable
tools. Such tool development will most likely hinge on more
widespread adoption of the PSI standards for quantitative
information, namely mzQuantML and mzTab.
There are, however, several protein expression databases,
most notably MOPED [113] and PaxDb [114], which can be
used to extract information about the expression levels of in-
dividual proteins. Both resources routinely make use of pub-
licly available data in PRIDE and PeptideAtlas, among others.
In PaxDb, identification data from filtered datasets are first
mapped onto a common namespace, and quantification val-
ues are then derived after reprocessing with a standardized
spectral counting pipeline. PaxDb is ameta-resource inwhich
protein expression is estimated across a number of species
(more than 50 at the time of writing), and recently even across
cell lines [115]. MOPED presents a multiomics resource for
human andmodel organisms, including at present gene, pro-
tein, and pathway expression information [116].
Another resource to highlight in this context is Pro-
teomicsDB, which provides abundance estimates according
to the label-free intensity-based iBAQ method [117]. Pro-
teomicsDB is one of the main outputs of the draft human
proteome by Wilhelm et al. [10], and represents a nice exam-
ple of data reprocessing. For their analysis, they combined
their own generated experimental results with publicly avail-
able data. In fact, around 40% of the data used to generate
this draft of the human proteome were obtained from public
resources such as PRIDE, MassIVE, and PeptideAtlas (see
Supporting Information Table 1 in [10] for the complete list).
However, new datasets are reprocessed regularly and incor-
porated into ProteomicsDB, including also RNAseq data and
phospho-proteomics experiments.
The ability to compare protein abundances among datasets
across public repositories would provide the possibility to vir-
tually create new quantitative experiments, paving the way
for in silico proteomics (Fig. 4). However, accurate absolute
quantification of peptides and proteins in datasets is made
challenging by the need for internal standards. Relative quan-
tification is impaired by the heterogeneity of the data present
in repositories, and their often suboptimal annotation [118].
It is therefore worth mentioning that in-depth annotation
of the experimental design is essential in order to correctly
interpret quantitative information from public proteomics
data.
The development of bioinformatics and statistics tools for
the robust and accurate interpretation of such heterogeneous
data will allow the setup of creative designs where datasets
fromdifferent sources can be repurposed and compared. This
could, for example, enable the in silico comparison of large
patient cohorts based on the aggregation of multiple smaller
cohorts. Such approaches can, however, be made impossible
if significant sample variability is introduced during sample
extraction and preparation, for example when PTM enrich-
ment is conducted.
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Figure 4. The rapidly growing amount of
publicly available proteomics data opens
up the opportunity for in silico proteomics,
that is using bioinformatics to test hy-
potheses directly through the available
data, instead of going via the generation
of new experimental data.
2 Discussion
The growing amount of publicly available proteomics data
has already been put to great use, both as a means to val-
idate published results and to generate new knowledge via
reprocessing and repurposing. With the achievement of the
requiredmilestones for data sharing (i.e. data standards, user-
friendly software, and public databases) and the push toward
public data from journals and funders, the amount of shared
data will only continue to grow rapidly.
There are, however, still some limiting factors that ought to
be addressed. The first of these is the need for proper annota-
tion, especially regarding experimental design. Indeed, even
thoughminimal reporting standards have been developed for
proteomics data (the so-called MIAPE (Minimum Informa-
tion About a Proteomics Experiment) guidelines [119]), there
remains a gap between what is reported and what ought to be
reported. While it is possible to attempt to infer the missing
information as, for example, done by the pride-asap pipeline
[120], this is often far from straightforward and may result
in incorrect assumptions. The only real solution is to make
it easier for submitters to provide additional information, or
to annotate this information automatically in the standard
file formats. This work has already started, notable in LIMS
systems such as MASPECTRAS [121], ms_lims [122], and
Proteios [123], but it will still take some time before it is
straightforward to capture all the desired information.
A related challenge is the provision of easy access to public
data while catering to the need for visual and interactive anal-
ysis [124]. There are already several tools, including PRIDE
Inspector [27] and PeptideShaker [72] that support this con-
cept, but more are certainly needed. This is especially true
for tools that link and display information from multiple re-
sources in a meaningful way. Easy access for developers is
also vital, for example, via systems such as BioMart [125], or
more recently, via web services [48, 49].
It is also crucial that scientists get credit for sharing their
data, especially when these data are reused in new contexts.
The ProteomeXchange accession number should therefore
always be used when a dataset is reused and the correspond-
ing publication(s) should be cited. ProteomeXchange also is-
sues a DOI (Digital Object Identifier) to “Complete” submis-
sions (i.e. submissions where data are provided in accordance
with public standards, so they are easier to access and reuse),
as a way to improve dataset tracking and to give credit to au-
thors [126]. It will also be useful if resources provide dataset
access statistics, given the current trend of putting increased
value on so-called “altmetrics” methods [127] to capture the
impact of scientists’ work.
Moving forward, data-independent acquisition approaches
such as MSE and SWATH-MS will become more popular in
the field [128]. And even though some public data for these
approaches already exist, it is expected that public deposition
of this type of data will significantly increase in the coming
years. In fact, there are already dedicated resources in place
such as SWATH-Atlas (http://www.swathatlas.org) that can
be used for planning SWATH experiments, for depositing ex-
periments, and for exploring the results of deposited datasets.
A particular characteristic of SWATH-MS data is that, once
generated, these can potentially be reanalyzed multiple times
using different spectral libraries, which are set to improve
over time as public data increase. These developments open
C© 2015 The Authors. Proteomics published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.proteomics-journal.com
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up numerous novel possibilities for the reanalysis of public
proteomics data.
Another very interesting upcoming opportunity is the re-
processing of datasets generated in “multi-omics” studies. At
present, these type of studies pose a challenge for both tra-
ditional repositories, which are most often field-specific (e.g.
proteomics, genomics, or transcriptomics), as well as for re-
searchers, given that at present it is not straightforward to link
public data coming from paired samples located in different
resources (e.g. MS proteomics and RNAseq data obtained
in the same study). There are, however, ongoing efforts to
link different studies performed on the same sample [129].
Over time, the existence of personalized sequence databases
(from DNA exome sequencing), or the existence of public
data containing both gene and protein expression data for
a given sample will become commonplace, opening up yet
more opportunities for data analysts.
Many of the approaches highlighted in this review can also
be exploited in the metabolomics field, where the first stable
data repositories and data standards are now starting to be
established [130]. For example, spectral libraries have been
used for the analysis of MSmetabolomics data already, many
years before the same approachwas applied to the proteomics
field, and we can expect to see more examples of techniques
adopted from related fields in the future.
Finally, the need for customizable, large-scale reprocessing
systems should be highlighted. Such capabilities currently
remain limited to a couple of dedicated proteomics bioin-
formatics groups. However, as the data have been generated
by the community, and thus belong to the community as a
whole, large-scale reprocessing should also be made avail-
able to the general community. Only then can we start to
realize the full potential of the publicly shared proteomics
data.
K.V. and L.M. acknowledge support from Ghent Uni-
versity (Multidisciplinary Research Partnership “Bioinformat-
ics: from nucleotides to networks”), Ghent University grant
BOF12/GOA/014, and the IWT SBO grant “INSPECTOR”
(120025). A.C. is supported by EMBL core funding. J.A.V. is
supported by theWellcome Trust (grant numberWT101477MA)
and the BBSRC (grant number BB/L024225/1). H.B. and H.R.
are supported by Bergen Forskningsstifelse, and H.R. is further
supported by Novo Nordisk Fonden and Western Norway Re-
gional Health Authority. F.B. is supported by the Kristian Ger-
hard Jebsen foundation.
The authors have declared no conflict of interest.
3 References
[1] Editors, Democratizing proteomics data. Nat. Biotechnol.
2007, 25, 262.
[2] Editors, Thou shalt share your data. Nat. Methods 2008, 5,
209–209.
[3] Burlingame, A. L., Carr, S. A., Bradshaw, R. A., Chalkley,
R. J., On credibility, clarity and compliance. Mol. Cell Pro-
teomics 2015, 7, 1731–1733.
[4] Martens, L., Hermjakob, H., Jones, P., Adamski, M. et al.,
PRIDE: the proteomics identifications database. Proteomics
2005, 5, 3537–3545.
[5] Craig, R., Cortens, J. P., Beavis, R. C., Open source system
for analyzing, validating, and storing protein identification
data. J. Proteome Res. 2004, 3, 1234–1242.
[6] Desiere, F., Deutsch, E. W., King, N. L., Nesvizhskii, A. I.
et al., The PeptideAtlas project. Nucleic Acids Res. 2006,
34, D655–D658.
[7] Farrah, T., Deutsch, E. W., Kreisberg, R., Sun, Z. et al., PAS-
SEL: the PeptideAtlas SRMexperiment library. Proteomics
2012, 12, 1170–1175.
[8] Sharma, V., Eckels, J., Taylor, G. K., Shulman, N. J. et al.,
Panorama: a targeted proteomics knowledge base. J. Pro-
teome Res. 2014, 13, 4205–4210.
[9] Reddy, T. B., Riley, R., Wymore, F., Montgomery, P. et al., TB
database: an integrated platform for tuberculosis research.
Nucleic Acids Res. 2009, 37, D499–D508.
[10] Wilhelm, M., Schlegl, J., Hahne, H., Moghaddas Gholami,
A. et al., Mass-spectrometry-based draft of the human pro-
teome. Nature 2014, 509, 582–587.
[11] Kim, M. S., Pinto, S. M., Getnet, D., Nirujogi, R. S. et al., A
draft map of the human proteome. Nature 2014, 509, 575–
581.
[12] Hirsch-Hoffmann, M., Gruissem, W., Baerenfaller, K.,
pep2pro: the high-throughput proteomics data processing,
analysis, and visualization tool. Front Plant Sci. 2012, 3,
123.
[13] Guldbrandsen, A., Vethe, H., Farag, Y., Oveland, E. et al., In-
depth characterization of the cerebrospinal fluid proteome
displayed through the CSF Proteome Resource (CSF-PR).
Mol. Cell Proteomics 2014, 11, 3152–3163.
[14] Colaert, N., Maddelein, D., Impens, F., Van Damme, P.
et al., The Online Protein Processing Resource (TOPPR):
a database and analysis platform for protein pro-
cessing events. Nucleic Acids Res. 2013, 41, D333–
D337.
[15] Lange, P. F., Overall, C. M., TopFIND, a knowledgebase link-
ing protein termini with function. Nat. Methods 2011, 8,
703–704.
[16] Perez-Riverol, Y., Alpi, E.,Wang, R., Hermjakob, H., Vizcaino,
J. A., Making proteomics data accessible and reusable: cur-
rent state of proteomics databases and repositories. Pro-
teomics 2014, 15, 930–949.
[17] Martens, L., Nesvizhskii, A. I., Hermjakob, H., Adamski, M.
et al., Do we want our data raw? Including binary mass
spectrometry data in public proteomics data repositories.
Proteomics 2005, 5, 3501–3505.
[18] Martens, L., Chambers, M., Sturm, M., Kessner, D. et al.,
mzML—a community standard formass spectrometry data.
Mol. Cell Proteomics 2011, 10, R110 000133.
[19] Jones, A. R., Eisenacher, M., Mayer, G., Kohlbacher,
O. et al., The mzIdentML data standard for mass
C© 2015 The Authors. Proteomics published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.proteomics-journal.com
222 M. Vaudel et al. Proteomics 2016, 16, 214–225
spectrometry-based proteomics results. Mol. Cell Pro-
teomics 2012, 11, M111 014381.
[20] Griss, J., Jones, A. R., Sachsenberg, T., Walzer, M. et al.,
The mzTab data exchange format: communicating mass-
spectrometry-based proteomics and metabolomics exper-
imental results to a wider audience. Mol. Cell Proteomics
2014, 13, 2765–2775.
[21] Walzer, M., Qi, D., Mayer, G., Uszkoreit, J. et al., The
mzQuantML data standard for mass spectrometry-based
quantitative studies in proteomics. Mol. Cell Proteomics
2013, 12, 2332–2340.
[22] Deutsch, E. W., Chambers, M., Neumann, S., Levander, F.
et al., TraML: a standard format for exchange of selected
reaction monitoring transition lists. Mol. Cell Proteomics
2011, 11, R111.015040.
[23] Chambers, M. C., Maclean, B., Burke, R., Amodei, D. et al.,
A cross-platform toolkit for mass spectrometry and pro-
teomics. Nat. Biotechnol. 2012, 30, 918–920.
[24] Cote, R. G., Griss, J., Dianes, J. A., Wang, R. et al.,
The PRoteomics IDEntification (PRIDE) Converter 2 frame-
work: an improved suite of tools to facilitate data sub-
mission to the PRIDE database and the ProteomeX-
change consortium. Mol. Cell Proteomics 2012, 11, 1682–
1689.
[25] Barsnes, H., Vizcaı´no, J. A., Eidhammer, I., Martens, L.,
PRIDE Converter: making proteomics data-sharing easy.
Nat. Biotechnol. 2009, 27, 598–599.
[26] Ghali, F., Krishna, R., Lukasse, P., Martinez-Bartolome, S.
et al., Tools (Viewer, Library and Validator) that facilitate use
of the peptide and protein identification standard format,
termed mzIdentML. Mol. Cell Proteomics 2013, 12, 3026–
3035.
[27] Wang, R., Fabregat, A., Rios, D., Ovelleiro, D. et al., PRIDE
Inspector: a tool to visualize and validate MS proteomics
data. Nat. Biotechnol. 2012, 30, 135–137.
[28] Vizcaı´no, J. A., Deutsch, E. W., Wang, R., Csordas, A.
et al., ProteomeXchange provides globally coordinated
proteomics data submission and dissemination. Nat.
Biotechnol. 2014, 32, 223–226.
[29] Barsnes, H., Martens, L., Crowdsourcing in proteomics:
public resources lead to better experiments. Amino Acids
2013, 44, 1129–1137.
[30] Rung, J., Brazma, A., Reuse of public genome-wide
gene expression data. Nat. Rev. Genet. 2013, 14,
89–99.
[31] UniProt Consortium, The universal protein resource
(UniProt). Nucleic Acids Res. 2008, 36, D190–D195.
[32] Lane, L., Argoud-Puy, G., Britan, A., Cusin, I. et al., neXtProt:
a knowledge platform for human proteins. Nucleic Acids
Res. 2012, 40, D76–D83.
[33] Hornbeck, P. V., Zhang, B., Murray, B., Kornhauser, J. M.
et al., PhosphoSitePlus, 2014: mutations, PTMs and recali-
brations. Nucleic Acids Res. 2015, 43, D512–D520.
[34] Fan, J., Mohareb, F., Bond, N. J., Lilley, K. S., Bessant, C.,
MRMaid 2.0: mining PRIDE for evidence-based SRM tran-
sitions. OMICS 2012, 16, 483–488.
[35] Mohammed, Y., Domanski, D., Jackson, A. M., Smith, D.
S. et al., PeptidePicker: a scientific workflow with web in-
terface for selecting appropriate peptides for targeted pro-
teomics experiments. J. Proteomics 2014, 106, 151–161.
[36] Mohammed, Y., Borchers, C. H., An extensive li-
brary of surrogate peptides for all human proteins.
J. Proteomics 2015, pii: S1874-3919(15)30079-8. doi:
10.1016/j.jprot.2015.07.025. [Epub ahead of print].
[37] Vandermarliere, E., Mueller, M., Martens, L., Getting in-
timate with trypsin, the leading protease in proteomics.
Mass Spectrom. Rev. 2013, 32, 453–465.
[38] Burkhart, J. M., Schumbrutzki, C., Wortelkamp, S., Sick-
mann, A., Zahedi, R. P., Systematic and quantitative
comparison of digest efficiency and specificity reveals
the impact of trypsin quality on MS-based proteomics. J.
Proteomics 2012, 75, 1454–1462.
[39] Fannes, T., Vandermarliere, E., Schietgat, L., Degroeve, S.
et al., Predicting tryptic cleavage from proteomics data us-
ing decision tree ensembles. J. Proteome Res. 2013, 12,
2253–2259.
[40] Moruz, L., Pichler, P., Stranzl, T., Mechtler, K., Kall, L., Opti-
mized nonlinear gradients for reversed-phase liquid chro-
matography in shotgun proteomics. Anal. Chem. 2013, 85,
7777–7785.
[41] Barsnes, H., Eidhammer, I., Martens, L., A global analysis
of peptide fragmentation variability. Proteomics 2011, 11,
1181–118.
[42] Degroeve, S., Martens, L., MS2PIP: a tool for MS/MS peak
intensity prediction. Bioinformatics 2013, 29, 3199–3203.
[43] Klie, S., Martens, L., Vizcaino, J. A., Cote, R. et al., Ana-
lyzing large-scale proteomics projects with latent semantic
indexing. J. Proteome Res. 2008, 7, 182–191.
[44] Omenn, G. S., States, D. J., Adamski, M., Blackwell, T. W.
et al., Overview of the HUPO Plasma Proteome Project:
results from the pilot phase with 35 collaborating labo-
ratories and multiple analytical groups, generating a core
dataset of 3020 proteins and a publicly-available database.
Proteomics 2005, 5, 3226–3245.
[45] Mueller, M., Vizcaino, J. A., Jones, P., Cote, R. et al.,
Analysis of the experimental detection of central nervous
system-related genes in human brain and cerebrospinal
fluid datasets. Proteomics 2008, 8, 1138–1148.
[46] Griss, J., Cote, R. G., Gerner, C., Hermjakob, H., Vizcaino, J.
A., Published and perished? The influence of the searched
protein database on the long-term storage of proteomics
data. Mol. Cell Proteomics 2011, 10, M111 008490.
[47] Kasprzyk, A., BioMart: driving a paradigm change in bio-
logical data management. Database 2011, 2011, bar049.
[48] Reisinger, F., Del-Toro, N., Ternent, T., Hermjakob, H., Viz-
caino, J. A., Introducing the PRIDE Archive RESTful web
services. Nucleic Acids Res. 2015, 43, W599–604.
[49] Fenyo, D., Beavis, R. C., The GPMDB REST interface. Bioin-
formatics 2015, 31, 2056–2058.
[50] Griss, J., Perez-Riverol, Y., Hermjakob, H., Vizcaino, J. A.,
Identifying novel biomarkers through data mining—a real-
istic scenario? Proteomics Clin. Appl. 2014, 9, 437–443.
C© 2015 The Authors. Proteomics published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.proteomics-journal.com
Proteomics 2016, 16, 214–225 223
[51] Frewen, B. E., Merrihew, G. E., Wu, C. C., Noble, W. S., Mac-
Coss, M. J., Analysis of peptide MS/MS spectra from large-
scale proteomics experiments using spectrum libraries.
Anal. Chem. 2006, 78, 5678–5684.
[52] Lam, H., Deutsch, E. W., Eddes, J. S., Eng, J. K. et al., De-
velopment and validation of a spectral library searching
method for peptide identification fromMS/MS. Proteomics
2007, 7(5), 655–667.
[53] Tabb, D. L., Thompson, M. R., Khalsa-Moyers, G., VerBerk-
moes, N. C., McDonald, W. H., MS2Grouper: group assess-
ment and synthetic replacement of duplicate proteomic
tandem mass spectra. J. Am. Soc. Mass Spectrom. 2005,
16(8), 1250–1261.
[54] Flikka, K., Meukens, J., Helsens, K., Vandekerckhove, J.
et al., Implementation and application of a versatile clus-
tering tool for tandemmass spectrometry data. Proteomics
2007, 7(18), 3245–3258.
[55] Falkner, J. A., Falkner, J. W., Yocum, A. K., Andrews, P.
C., A spectral clustering approach to MS/MS identification
of post-translational modifications. J. Proteome Res. 2008,
7(11), 4614–4622.
[56] Frank, A. M., Bandeira, N., Shen, Z., Tanner, S. et al., Clus-
tering millions of tandem mass spectra. J. Proteome Res.
2008, 7(1), 113–122.
[57] Frank, A. M., Monroe, M. E., Shah, A. R., Carver, J. J.
et al., Spectral archives: extending spectral libraries to ana-
lyze both identified and unidentified spectra. Nat. Methods
2011, 8(7), 587–591.
[58] Griss, J., Foster, J. M., Hermjakob, H., Vizcaino, J. A., PRIDE
Cluster: building a consensus of proteomics data. Nat.
Methods 2013, 10(2), 95–96.
[59] Lam, H., Spectral archives: a vision for future pro-
teomics data repositories. Nat. Methods 2011, 8(7), 546–
548.
[60] Ghesquiere, B., Helsens, K., Vandekerckhove, J., Gevaert,
K., A stringent approach to improve the quality of nitrotyro-
sine peptide identifications. Proteomics 2011, 11(6), 1094–
1098.
[61] Craig, R., Beavis, R. C., TANDEM: matching proteins with
tandem mass spectra. Bioinformatics 2004, 20(9), 1466–
1467.
[62] Deutsch, E.W.,Mendoza, L., Shteynberg, D., Slagel, J. et al.,
Trans-Proteomic Pipeline, a standardized data processing
pipeline for large-scale reproducible proteomics informat-
ics. Proteomics Clin. Appl. 2015, 9, 745–754.
[63] Vialas, V., Sun, Z., Loureiro y Penha, C. V., Carrascal, M.
et al., A Candida albicans PeptideAtlas. J. Proteomics 2014,
97, 62–68.
[64] Bundgaard, L., Jacobsen, S., Sorensen, M. A., Sun, Z.
et al., The Equine Peptideatlas: a resource for developing
proteomics-based veterinary research. Proteomics 2014,
14(6), 763–773.
[65] Aebersold, R., Bader, G. D., Edwards, A. M., van Eyk, J. E.
et al., The biology/disease-driven human proteome project
(B/D-HPP): enabling protein research for the life sciences
community. J. Proteome Res. 2013, 12(1), 23–27.
[66] Paik, Y. K., Jeong, S. K., Omenn, G. S., Uhlen, M. et al.,
The Chromosome-Centric Human Proteome Project for cat-
aloging proteins encoded in the genome. Nat. Biotechnol.
2012, 30(3), 221–223.
[67] Uhlen, M., Fagerberg, L., Hallstrom, B. M., Lindskog, C.
et al., Proteomics. Tissue-based map of the human pro-
teome. Science 2015, 347(6220), 1260419.
[68] Horvatovich, P., Lundberg, E. K., Chen, Y. J., Sung, T. Y. et al.,
A quest formissing proteins: update 2015 onChromosome-
Centric Human Proteome Project. J. Proteome Res. 2015,
14, 3415–3431.
[69] Baker, P. R., Chalkley, R. J., MS-viewer: a web-based spec-
tral viewer for proteomics results. Mol. Cell Proteomics
2014, 13(5), 1392–1396.
[70] Helsens, K., Timmerman, E., Vandekerckhove, J., Gevaert,
K., Martens, L., Peptizer, a tool for assessing false positive
peptide identifications andmanually validating selected re-
sults. Mol. Cell Proteomics 2008, 7(12), 2364–2372.
[71] Sturm, M., Kohlbacher, O., TOPPView: an open-source
viewer for mass spectrometry data. J. Proteome Res. 2009,
8(7), 3760–3763.
[72] Vaudel, M., Burkhart, J. M., Zahedi, R. P., Oveland, E.
et al., PeptideShaker enables reanalysis of MS-derived
proteomics data sets. Nat. Biotechnol. 2015, 33(1), 22–
24.
[73] Farag, Y., Berven, F. S., Jonassen, I., Petersen, K., Barsnes,
H., Distributed and interactive visual analysis of omics
data. J. Proteomics 2015, pii: S1874-3919(15)30030-0. doi:
10.1016/j.jprot.2015.05.029. [Epub ahead of print].
[74] Asara, J. M., Schweitzer, M. H., Freimark, L. M., Phillips,
M., Cantley, L. C., Protein sequences from mastodon and
Tyrannosaurus rex revealed bymass spectrometry.Science
2007, 316(5822), 280–285.
[75] Asara, J. M., Garavelli, J. S., Slatter, D. A., Schweitzer, M.
H. et al., Interpreting sequences frommastodon and T. rex.
Science 2007, 317(5843), 1324–1325.
[76] Buckley,M.,Walker, A., Ho, S. Y., Yang, Y. et al., Comment on
“Protein sequences frommastodon and Tyrannosaurus rex
revealed by mass spectrometry”. Science 2008, 319(5859),
33.
[77] Pevzner, P. A., Kim, S., Ng, J., Comment on Protein se-
quences from mastodon and Tyrannosaurus rex revealed
by mass spectrometry”. Science 2008, 321(5892), 1040.
[78] Bern, M., Phinney, B. S., Goldberg, D., Reanalysis of Tyran-
nosaurus rex mass spectra. J. Proteome Res. 2009, 8(9),
4328–4332.
[79] Bromenshenk, J. J., Henderson, C. B., Wick, C. H., Stanford,
M. F. et al., Iridovirus and microsporidian linked to honey
bee colony decline. PLoS One 2010, 5(10), e13181.
[80] Knudsen, G. M., Chalkley, R. J., The effect of using an in-
appropriate protein database for proteomic data analysis.
PLoS One 2011, 6(6), e20873.
[81] Foster, L. J., Bromenshenk et al., (PLoS One, 2011,
5(10):e13181) have claimed to have found peptides from an
invertebrate iridovirus in bees. Mol. Cell Proteomics 2012,
11(1), A110 0063871.
C© 2015 The Authors. Proteomics published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.proteomics-journal.com
224 M. Vaudel et al. Proteomics 2016, 16, 214–225
[82] Foster, L. J., Interpretation of data underlying the link be-
tween colony collapse disorder (CCD) and an invertebrate
iridescent virus. Mol. Cell Proteomics 2011, 10(3), M110
006387.
[83] Noble, W. S., Mass spectrometrists should search only for
peptides they care about. Nat. Methods 2015, 12(7), 605–
608.
[84] Daughenbaugh, K. F., Martin, M., Brutscher, L. M., Cavigli, I.
et al., Honey bee infecting Lake Sinai viruses. Viruses 2015,
7(6), 3285–3309.
[85] Ezkurdia, I., Vazquez, J., Valencia, A., Tress, M., Analyzing
the first drafts of the human proteome. J. Proteome Res.
2014, 13, 3854–3855.
[86] Brosch, M., Saunders, G. I., Frankish, A., Collins, M. O.
et al., Shotgun proteomics aids discovery of novel protein-
coding genes, alternative splicing, and “resurrected” pseu-
dogenes in the mouse genome. Genome Res. 2011, 21(5),
756–767.
[87] Volders, P. J., Verheggen, K., Menschaert, G., Vandepoele,
K. et al., An update on LNCipedia: a database for annotated
human lncRNA sequences. Nucleic Acids Res. 2015, 43(8),
4363–4364.
[88] Ezkurdia, I., del Pozo, A., Frankish, A., Rodriguez, J. M.
et al., Comparative proteomics reveals a significant bias
toward alternative protein isoforms with conserved struc-
ture and function. Mol. Biol. Evol. 2012, 29(9), 2265–
2283.
[89] Ezkurdia, I., Juan, D., Rodriguez, J. M., Frankish, A. et al.,
Multiple evidence strands suggest that theremay be as few
as 19,000 human protein-coding genes. Hum. Mol. Genet.
2014, 23(22), 5866–5878.
[90] Abascal, F., Ezkurdia, I., Rodriguez-Rivas, J., Rodriguez, J.
M. et al., Alternatively spliced homologous exons have an-
cient origins and are highly expressed at the protein level.
PLoS Comput. Biol. 2015, 11(6), e1004325.
[91] Swindell, W. R., Remmer, H. A., Sarkar, M. K., Xing, X.
et al., Proteogenomic analysis of psoriasis reveals discor-
dant and concordant changes in mRNA and protein abun-
dance. Genome Med. 2015, 7(1), 86.
[92] Barrett, T., Wilhite, S. E., Ledoux, P., Evangelista, C. et al.,
NCBI GEO: archive for functional genomics data sets—
update. Nucleic Acids Res. 2013, 41(Database issue), D991–
D995.
[93] Zhu, Y., Hultin-Rosenberg, L., Forshed, J., Branca, R. M.
et al., SpliceVista, a tool for splice variant identification
and visualization in shotgun proteomics data.Mol. Cell Pro-
teomics 2014, 13(6), 1552–1562.
[94] Nesvizhskii, A. I., Proteogenomics: concepts, applications
and computational strategies. Nat. Methods 2014, 11(11),
1114–1125.
[95] Koch, A., Gawron, D., Steyaert, S., Ndah, E. et al., A pro-
teogenomics approach integrating proteomics and ribo-
some profiling increases the efficiency of protein identifi-
cation and enables the discovery of alternative translation
start sites. Proteomics 2014, 14(23–24), 2688–2698.
[96] Crappe, J., Ndah, E., Koch, A., Steyaert, S. et al., PRO-
TEOFORMER: deep proteome coverage through ribosome
profiling andMS integration.Nucleic Acids Res. 2015, 43(5),
e29.
[97] Vaudel, M., Sickmann, A., Martens, L., Current methods
for global proteome identification. Expert Rev. Proteomics
2012, 9(5), 519–532.
[98] Chalkley, R. J., Clauser, K. R., Modification site localization
scoring: strategies and performance. Mol. Cell Proteomics
2012, 11(5), 3–14.
[99] Beausoleil, S. A., Villen, J., Gerber, S. A., Rush, J., Gygi, S. P.,
A probability-based approach for high-throughput protein
phosphorylation analysis and site localization.Nat. Biotech-
nol. 2006, 24(10), 1285–1292.
[100] Olsen, J. V., Blagoev, B., Gnad, F., Macek, B. et al.,
Global, in vivo, and site-specific phosphorylation dy-
namics in signaling networks. Cell 2006, 127(3), 635–
648.
[101] Savitski, M. M., Lemeer, S., Boesche, M., Lang, M. et al.,
Confident phosphorylation site localization using the Mas-
cot Delta Score. Mol. Cell Proteomics 2011, 10(2), M110
003830.
[102] Taus, T., Kocher, T., Pichler, P., Paschke, C. et al., Uni-
versal and confident phosphorylation site localization us-
ing phosphoRS. J. Proteome Res. 2011, 10(12), 5354–
5362.
[103] Vaudel, M., Breiter, D., Beck, F., Rahnenfuhrer, J. et al., D-
score: a search engine independent MD-score. Proteomics
2013, 13(6), 1036–1041.
[104] Fermin, D.,Walmsley, S. J., Gingras, A. C., Choi, H., Nesvizh-
skii, A. I., LuciPHOr: algorithm for phosphorylation site lo-
calization with false localization rate estimation usingmod-
ified target-decoy approach. Mol. Cell Proteomics 2013,
12(11), 3409–3419.
[105] Fermin, D., Avtonomov, D., Choi, H., Nesvizhskii, A. I., Luci-
PHOr2: site localization of generic post-translational mod-
ifications from tandem mass spectrometry data. Bioinfor-
matics 2015, 31(7), 1141–1143.
[106] Vandermarliere, E., Martens, L., Protein structure as a
means to triage proposed PTM sites. Proteomics 2013,
13(6), 1028–1035.
[107] Chick, J. M., Kolippakkam, D., Nusinow, D. P., Zhai, B.
et al., A mass-tolerant database search identifies a large
proportion of unassigned spectra in shotgun proteomics
as modified peptides. Nat. Biotechnol. 2015, 33(7), 743–
749.
[108] Loroch, S., Dickhut, C., Zahedi, R. P., Sickmann, A.,
Phosphoproteomics—more than meets the eye. Elec-
trophoresis 2013, 34(11), 1483–1492.
[109] Olsen, J. V.,Mann,M., Status of large-scale analysis of post-
translationalmodifications bymass spectrometry.Mol. Cell
Proteomics 2013, 12(12), 3444–3452.
[110] Solari, F. A., Dell’Aica, M., Sickmann, A., Zahedi, R. P.,
Why phosphoproteomics is still a challenge. Mol. Biosyst.
2015, 11, 1487–1493.
[111] Matic, I., Ahel, I., Hay, R. T., Reanalysis of phosphopro-
teomics data uncovers ADP-ribosylation sites. Nat. Meth-
ods 2012, 9(8), 771–772.
C© 2015 The Authors. Proteomics published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.proteomics-journal.com
Proteomics 2016, 16, 214–225 225
[112] Hahne, H., Kuster, B., Discovery of O-GlcNAc-6-phosphate
modified proteins in large-scale phosphoproteomics data.
Mol. Cell Proteomics 2012, 11(10), 1063–1069.
[113] Kolker, E., Higdon, R., Haynes, W., Welch, D. et al., MOPED:
model organism protein expression database. Nucleic
Acids Res. 2012, 40(Database issue), D1093–D1099.
[114] Wang, M., Weiss, M., Simonovic, M., Haertinger, G. et al.,
PaxDb, a database of protein abundance averages across
all three domains of life. Mol. Cell Proteomics 2012, 11(8),
492–500.
[115] Wang, M., Herrmann, C. J., Simonovic, M., Szklarczyk, D.,
von Mering, C., Version 4.0 of PaxDb: Protein abundance
data, integrated across model organisms, tissues, and cell-
lines. Proteomics 2015, 15, 3163–3168.
[116] Montague, E., Janko, I., Stanberry, L., Lee, E. et al., Be-
yond protein expression, MOPED goes multi-omics. Nu-
cleic Acids Res. 2015, 43(Database issue), D1145–D1151.
[117] Schwanhausser, B., Busse, D., Li, N., Dittmar, G. et al.,
Global quantification of mammalian gene expression con-
trol. Nature 2011, 473(7347), 337–342.
[118] Gonnelli, G., Hulstaert, N., Degroeve, S., Martens, L., To-
wards a human proteomics atlas. Anal. Bioanal. Chem.
2012, 404(4), 1069–1077.
[119] Taylor, C. F., Paton, N. W., Lilley, K. S., Binz, P. A. et al.,
The minimum information about a proteomics experiment
(MIAPE). Nat. Biotechnol. 2007, 25(8), 887–893.
[120] Hulstaert, N., Reisinger, F., Rameseder, J., Barsnes, H. et al.,
Pride-asap: automatic fragment ion annotation of identified
PRIDE spectra. J. Proteomics 2013, 95, 89–92.
[121] Hartler, J., Thallinger, G. G., Stocker, G., Sturn, A. et al.,
MASPECTRAS: a platform for management and analysis
of proteomics LC-MS/MS data. BMC Bioinform. 2007, 8,
197.
[122] Helsens, K., Colaert, N., Barsnes, H., Muth, T. et al., ms_lims,
a simple yet powerful open source laboratory informa-
tion management system for MS-driven proteomics. Pro-
teomics 2010, 10(6), 1261–1264.
[123] Hakkinen, J., Vincic, G., Mansson, O., Warell, K., Levander,
F., The proteios software environment: an extensible mul-
tiuser platform formanagement and analysis of proteomics
data. J. Proteome Res. 2009, 8(6), 3037–3043.
[124] Oveland, E., Muth, T., Rapp, E., Martens, L. et al., View-
ing the proteome: how to visualize proteomics data? Pro-
teomics 2014, 15, 1341–1355.
[125] Smedley, D., Haider, S., Ballester, B., Holland, R. et al.,
BioMart—biological queries made easy. BMC Genomics
2009, 10, 22.
[126] Credit where credit is overdue. Nat. Biotechnol. 2009, 27(7),
579.
[127] Priem, J., Scholarship: beyond the paper. Nature 2013,
495(7442), 437–440.
[128] Law, K. P., Lim, Y. P., Recent advances in mass spec-
trometry: data independent analysis and hyper reac-
tion monitoring. Expert Rev. Proteomics 2013, 10(6),
551–566.
[129] Faulconbridge, A., Burdett, T., Brandizi, M., Gostev,M. et al.,
Updates to BioSamples database at European Bioinformat-
ics Institute. Nucleic Acids Res. 2014, 42(Database issue),
D50–D52.
[130] Salek, R. M., Haug, K., Conesa, P., Hastings, J. et al.,
The MetaboLights repository: curation challenges in
metabolomics. Database 2013, 2013, bat029.
C© 2015 The Authors. Proteomics published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.proteomics-journal.com
